Abstract
Objective MR-guided focused ultrasound (MRgFUS) thalamotomy is a novel and effective treatment for medication-refractory tremor in essential tremor (ET), but how the brain responds to this deliberate lesion is not clear. The current study aimed to evaluate the immediate and longitudinal alterations of functional networks after MRgFUS thalamotomy.
Methods We retrospectively obtained preoperative and postoperative 30-day, 90-day, and 180-day data of 31 ET patients subjected with MRgFUS thalamotomy from 2018 to 2020. Their archived resting-state functional MRI data were used to functional network comparison as well as graph-theory metrics analysis. Both partial least squares (PLS) regression and linear regression were conducted to associate functional features to tremor symptoms.
Results MRgFUS thalamotomy dramatically abolished tremors, while global functional network only sustained immediate fluctuation within one week postoperatively. Network-based statistics have identified a long-term enhanced corticostriatal subnetwork by comparison between 180-day and preoperative data (P = 0.019). Within this subnetwork, network degree, global efficiency and transitivity were significantly recovered in ET patients right after MRgFUS thalamotomy compared to the pre-operative timepoint (P < 0.05), as well as hemisphere lateralization (P < 0.001). The PLS main component significantly accounted for 33.68% and 34.16% of the total variances of hand tremor score and clinical rating scale for tremor (CRST)-total score (P = 0.037 and 0.027). Network transitivity of this subnetwork could serve as a reliable biomarker for hand tremor score control prediction at 180-day postoperatively (β = 2.94, P = 0.03).
Conclusions MRgFUS thalamotomy promoted corticostriatal connectivity activation correlated with tremor improvement in ET patient after MRgFUS thalamotomy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by National Natural Science Foundation of China 82151309 and 81825012 to XL as well as China Postdoctoral Science Foundation 2022T150788 to JJL.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The present study is retrospective, which was registered in clinicaltrials.gov with NCT04570046 to investigate the functional MR images related to MRgFUS thalamotomy in Chinese PLA General Hospital from 2018 to September 2020. It was approved by the institutional review board and the independent scientific advisory committee at Chinese PLA General Hospital. The data were anonymous, and the requirement for informed consent was therefore waived. Briefly, the image data of ET patients were enrolled in clinical trial of NCT03253991, which was an interventional study to evaluate the effectiveness and safety of ExAblate MRgFUS in 2017. Until September 2020, a total of 31 of these patients successfully completed preoperative and postoperative of imaging follow-up and tremor assessment, and all these data were collected for the retrospective study. Resting state functional MRI scanning was performed pre-operatively, and at 1-day, 7-day, 30-day, 90-day and 180-day postoperatively. Additional data of 31 healthy controls with matched the sex, age and education with ET patients were collected during the same period.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The conditions of our ethics approval do not permit public archiving of raw data. All code and statistical image data are available at https://github.com/louxin-lab.